The response of patients with neuromuscular disorders to muscle relaxants: a review.
D000690:Amyotrophic Lateral Sclerosis / Q000150:complications; D003472:Curare; D006429:Hemiplegia / Q000150:complications; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D008305:Malignant Hyperthermia / Q000209:etiology; D009103:Multiple Sclerosis / Q000150:complications; D009125:Muscle Relaxants, Central / Q000009:adverse effects*; D009136:Muscular Dystrophies / Q000150:complications; D009157:Myasthenia Gravis / Q000150:complications; D009222:Myotonia / Q000150:complications; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects*; D009468:Neuromuscular Diseases / Q000150:complications*; D010243:Paralysis / Q000139:chemically induced / Q000150:complications; D010300:Parkinson Disease / Q000150:complications; D010523:Peripheral Nervous System Diseases / Q000150:complications; D011051:Poliomyelitis / Q000150:complications; D012306:Risk; D013390:Succinylcholine / Q000009:adverse effects; D013514:Surgical Procedures, Operative; D009435:Synaptic Transmission / Q000187:drug effects; D013742:Tetanus / Q000150:complications
D009125:Muscle Relaxants, Central; D009467:Neuromuscular Depolarizing Agents; D003472:Curare; D013390:Succinylcholine